Genmab A/S's Arzerra® Third Quarter 2013 Net Sales Figures

Copenhagen, Denmark; October 23, 2013 – Genmab A/S (OMX: GEN) announced today that the Arzerra (ofatumumab) net sales during the third quarter of 2013 were GBP 17.8 million (approximately DKK 155 million). This figure consists of net sales in the US of GBP 13.1 million and in the rest of the world of GBP 4.7 million. Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 31 million.

Help employers find you! Check out all the jobs and post your resume.